Back to Search
Start Over
Looking beyond pulmonary disease in COVID-19: A lesson from patients with cystic fibrosis.
- Source :
-
Medical hypotheses [Med Hypotheses] 2021 Feb; Vol. 147, pp. 110481. Date of Electronic Publication: 2021 Jan 04. - Publication Year :
- 2021
-
Abstract
- Coronavirus disease 2019 (COVID-19) caused more than 52.775.271 million confirmed cases, 1.293.106 deaths, globally, and afflicted 208 countries, areas, or territories; and almost three months have passed since the World Health Organisation (WHO) declared COVID-19 as a pandemic. Despite the dramatic and global impact of the Coronavirus, the knowledge about the SARS-CoV-2 infection has been improved remarkably. Herein, we provided the rationale for SARS-CoV-2 infection as endothelial dysfunction rather than respiratory disease. Accordingly, we strongly invited the researchers to look beyond pulmonary injury and shift their attention from respiratory disease to endothelial disorder. This strategy could be particularly relevant to identifying therapeutic weapons stabilizing the endothelium rather than the lungs.<br /> (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Subjects :
- Antibodies, Monoclonal, Humanized therapeutic use
Antiviral Agents therapeutic use
Critical Illness
Endothelium, Vascular metabolism
Humans
Inflammation
Lung
Pandemics
COVID-19 complications
Cystic Fibrosis complications
Cystic Fibrosis drug therapy
Lung Diseases complications
Lung Diseases drug therapy
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 1532-2777
- Volume :
- 147
- Database :
- MEDLINE
- Journal :
- Medical hypotheses
- Publication Type :
- Editorial & Opinion
- Accession number :
- 33421691
- Full Text :
- https://doi.org/10.1016/j.mehy.2020.110481